235 results on '"Zoeller, R. Thomas"'
Search Results
202. European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation.
- Author
-
Zoeller RT, Birnbaum LS, Collins TJ, Heindel J, Hunt PA, Iguchi T, Kortenkamp A, Myers JP, Vom Saal FS, Sonnenschein C, and Soto AM
- Abstract
The European Food Safety Authority (EFSA) has revised their estimate of the toxicity of bisphenol A (BPA) and, as a result, have recommended reducing the tolerable daily intake (TDI) by 20 000-fold. This would essentially ban the use of BPA in food packaging such as can liners, plastic food containers, and in consumer products. To come to this conclusion, EFSA used a systematic approach according to a pre-established protocol and included all guideline and nonguideline studies in their analysis. They found that Th-17 immune cells increased with very low exposure to BPA and used this endpoint to revise the TDI to be human health protective. A number of regulatory agencies including the European Medicines Agency (EMA) have written formal disagreements with several elements of EFSA's proposal. The European Commission will now decide whether to accept EFSA's recommendation over the objections of EMA. If the Commission accepts EFSA's recommendation, it will be a landmark action using knowledge acquired through independent scientific studies focused on biomarkers of chronic disease to protect human health. The goal of this Perspective is to clearly articulate the monumental nature of this debate and decision and to explain what is at stake. Our perspective is that the weight of evidence clearly supports EFSA's proposal to reduce the TDI by 20 000-fold., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2023
- Full Text
- View/download PDF
203. Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA's criteria.
- Author
-
Vandenberg LN, Zoeller RT, Prins GS, and Trasande L
- Subjects
- United States, United States Food and Drug Administration, Food Safety
- Abstract
Background: In the US, the Food and Drug Administration (US FDA) is charged with protecting the safety of food from both pathogens and chemicals used in food production and food packaging. To protect the public in a transparent manner, the FDA needs to have an operational definition of what it considers to be an "adverse effect" so that it can take action against harmful agents. The FDA has recently published two statements where, for the first time, it defines the characteristics of an adverse effect that it uses to interpret toxicity studies., Objective: In this brief review, we examine two recent actions by the FDA, a proposed rule regarding a color additive used in vegetarian burgers and a decision not to recall fish with high levels of scombrotoxin. We evaluated the FDA's description of the criteria used to determine which outcomes should be considered adverse., Overview: We describe three reasons why the FDA's criteria for "adverse effects" is not public health protective. These include an unscientific requirement for a monotonic dose response, which conflates hazard assessment and dose response assessment while also ignoring evidence for non-linear and non-monotonic effects for many environmental agents; a requirement that the effect be observed in both sexes, which fails to acknowledge the many sex- and gender-specific effects on physiology, disease incidence and severity, and anatomy; and a requirement that the effects are irreversible, which does not acknowledge the role of exposure timing or appreciate transgenerational effects that have been demonstrated for environmental chemicals., Conclusions: The FDA's criteria for identifying adverse effects are inadequate because they are not science-based. Addressing this is important, because the acknowledgement of adverse effects is central to regulatory decisions and the protection of public health., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
204. Urinary Phthalate Biomarkers and Bone Mineral Density in Postmenopausal Women.
- Author
-
Reeves KW, Vieyra G, Grimes NP, Meliker J, Jackson RD, Wactawski-Wende J, Wallace R, Zoeller RT, Bigelow C, Hankinson SE, Manson JE, Cauley JA, and Calafat AM
- Subjects
- Absorptiometry, Photon, Aged, Biomarkers urine, Case-Control Studies, Creatinine urine, Cross-Sectional Studies, Environmental Exposure analysis, Estrogen Replacement Therapy, Female, Femur Neck diagnostic imaging, Humans, Longitudinal Studies, Middle Aged, Osteoporosis, Postmenopausal complications, Osteoporosis, Postmenopausal diagnostic imaging, Osteoporosis, Postmenopausal prevention & control, Osteoporotic Fractures etiology, Osteoporotic Fractures prevention & control, Pelvic Bones diagnostic imaging, Prospective Studies, Risk Factors, Women's Health, Biological Monitoring, Bone Density, Endocrine Disruptors urine, Phthalic Acids urine, Postmenopause urine
- Abstract
Context: Phthalates are endocrine-disrupting chemicals that could disrupt normal physiologic function, triggering detrimental impacts on bone., Objective: We evaluated associations between urinary phthalate biomarkers and BMD in postmenopausal women participating in the prospective Women's Health Initiative (WHI)., Methods: We included WHI participants enrolled in the BMD substudy and selected for a nested case-control study of phthalates and breast cancer (N = 1255). We measured 13 phthalate biomarkers and creatinine in 2 to 3 urine samples per participant collected over 3 years, when all participants were cancer free. Total hip and femoral neck BMD were measured at baseline and year 3, concurrent with urine collection, via dual-energy x-ray absorptiometry. We fit multivariable generalized estimating equation models and linear mixed-effects models to estimate cross-sectional and longitudinal associations, respectively, with stratification on postmenopausal hormone therapy (HT) use., Results: In cross-sectional analyses, mono-3-carboxypropyl phthalate and the sum of di-isobutyl phthalate metabolites were inversely associated with total hip BMD among HT nonusers, but not among HT users. Longitudinal analyses showed greater declines in total hip BMD among HT nonusers and with highest concentrations of mono-3-carboxyoctyl phthalate (-1.80%; 95% CI, -2.81% to -0.78%) or monocarboxynonyl phthalate (-1.84%; 95% CI, -2.80% to -0.89%); similar associations were observed with femoral neck BMD. Among HT users, phthalate biomarkers were not associated with total hip or femoral neck BMD change., Conclusion: Certain phthalate biomarkers are associated with greater percentage decreases in total hip and femoral neck BMD. These findings suggest that phthalate exposure may have clinically important effects on BMD, and potentially fracture risk., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
205. Endocrine disrupting chemicals and thyroid hormone action.
- Author
-
Zoeller RT
- Subjects
- Animals, Humans, Thyroid Hormones, Thyroxine, Triiodothyronine, Endocrine Disruptors toxicity, Polychlorinated Biphenyls
- Abstract
Thyroid hormones (predominantly thyroxine, T4, and triiodothyronine, T3) are essential for normal development and for adult physiology. There are several challenges, however, that make identifying chemicals that produce adverse effects by interfering with the thyroid system difficult. First, individual variability in serum concentrations of thyroid hormones represent only about 10% of the population reference range that is considered to be "normal." This means that populations studies evaluating the relationship between chemical exposure and serum thyroid hormones must be large enough to overcome this internal variance. In addition, we know that there are chemicals that do not produce changes in thyroid hormone levels, but nevertheless impact thyroid signaling in target tissues. A good example is that of polychlorinated biphenyls (PCBs). PCB exposure during development are clearly associated with cognitive deficits in humans. But PCB exposure isn't uniformly associated with a reduction in serum thyroid hormone in human populations despite mechanistic studies showing that PCBs reduce serum T4 in animals. In contrast, perchlorate is a chemical that inhibits iodide uptake, thereby reducing thyroid hormone synthesis and serum hormone levels. Human studies have been variable in identifying a relationship between thyroid hormone and perchlorate exposure, but studies also show that dietary iodine, cigarette smoking and other factors can modify this relationship. The conclusion is that identifying chemicals that interfere with thyroid hormone could depend on in vitro analysis of chemicals that interact with different proteins important for thyroid hormone to function properly., Competing Interests: Conflict of interest The author has not received funding from any source for this chapter. The views expressed here are the professional opinions of the author and do not necessarily reflect those of his employers or any agencies that have funded his work. There are no contractual relations or proprietary considerations that restrict the authors' publication or dissemination of the findings described in the manuscript. Dr. Zoeller has served on various advisory boards and panels of the US EPA, the National Institutes of Health and Pew Charitable Trusts in relation to issues of EDCs. He is currently a member of the Endocrine Society's EDC Advisory Group and is co-chair of one of its Task Force groups. His travel has been sponsored by various government, academic, and industry groups to present findings of his research. Dr. Zoeller's research has been funded by government agencies in the United States and the European Union., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
206. Data integration, analysis, and interpretation of eight academic CLARITY-BPA studies.
- Author
-
Heindel JJ, Belcher S, Flaws JA, Prins GS, Ho SM, Mao J, Patisaul HB, Ricke W, Rosenfeld CS, Soto AM, Vom Saal FS, and Zoeller RT
- Subjects
- Animals, Behavior, Animal drug effects, DNA Methylation, Female, Gene Expression Regulation, Developmental drug effects, Heart drug effects, Heart growth & development, Male, Mammary Glands, Animal drug effects, Mammary Glands, Animal growth & development, Ovary drug effects, Ovary growth & development, Pregnancy, Prenatal Exposure Delayed Effects genetics, Prostate drug effects, Prostate growth & development, Rats, Sprague-Dawley, Reproducibility of Results, Thyroid Gland drug effects, Thyroid Gland growth & development, Urethra drug effects, Urethra growth & development, Benzhydryl Compounds toxicity, Endocrine Disruptors toxicity, Maternal-Fetal Exchange, Phenols toxicity, Prenatal Exposure Delayed Effects chemically induced
- Abstract
"Consortium Linking Academic and Regulatory Insights on BPA Toxicity" (CLARITY-BPA) was a comprehensive "industry-standard" Good Laboratory Practice (GLP)-compliant 2-year chronic exposure study of bisphenol A (BPA) toxicity that was supplemented by hypothesis-driven independent investigator-initiated studies. The investigator-initiated studies were focused on integrating disease-associated, molecular, and physiological endpoints previously found by academic scientists into an industry standard guideline-compliant toxicity study. Thus, the goal of this collaboration was to provide a more comprehensive dataset upon which to base safety standards and to determine whether industry-standard tests are as sensitive and predictive as molecular and disease-associated endpoints. The goal of this report is to integrate the findings from the investigator-initiated studies into a comprehensive overview of the observed impacts of BPA across the multiple organs and systems analyzed. For each organ system, we provide the rationale for the study, an overview of methodology, and summarize major findings. We then compare the results of the CLARITY-BPA studies across organ systems with the results of previous peer-reviewed studies from independent labs. Finally, we discuss potential influences that contributed to differences between studies. Developmental exposure to BPA can lead to adverse effects in multiple organs systems, including the brain, prostate gland, urinary tract, ovary, mammary gland, and heart. As published previously, many effects were at the lowest dose tested, 2.5μg/kg /day, and many of the responses were non-monotonic. Because the low dose of BPA affected endpoints in the same animals across organs evaluated in different labs, we conclude that these are biologically - and toxicologically - relevant., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
207. Thresholds and Endocrine Disruptors: An Endocrine Society Policy Perspective.
- Author
-
Demeneix B, Vandenberg LN, Ivell R, and Zoeller RT
- Abstract
The concept of a threshold of adversity in toxicology is neither provable nor disprovable. As such, it is not a scientific question but a theoretical one. Yet, the belief in thresholds has led to traditional ways of interpreting data derived from regulatory guideline studies of the toxicity of chemicals. This includes, for example, the use of standard "uncertainty factors" when a "No Adverse Effect Level" (or similar "benchmark dose") is either observed, or not observed. In the context of endocrine-disrupting chemicals (EDCs), this approach is demonstrably inappropriate. First, the efficacy of a hormone on different endpoints can vary by several orders of magnitude. This feature of hormone action also applies to EDCs that can interfere with that hormone. For this reason, we argue that the choice of endpoint for use in regulation is critical, but note that guideline studies were not designed with this in mind. Second, the biological events controlled by hormones in development not only change as development proceeds but are different from events controlled by hormones in the adult. Again, guideline endpoints were also not designed with this in mind, especially since the events controlled by hormones can be both temporally and spatially specific. The Endocrine Society has laid out this logic over several years and in several publications. Rather than being extreme views, they represent what is known about hormones and the chemicals that can interfere with them., (© Endocrine Society 2020.)
- Published
- 2020
- Full Text
- View/download PDF
208. Removing Critical Gaps in Chemical Test Methods by Developing New Assays for the Identification of Thyroid Hormone System-Disrupting Chemicals-The ATHENA Project.
- Author
-
Kortenkamp A, Axelstad M, Baig AH, Bergman Å, Bornehag CG, Cenijn P, Christiansen S, Demeneix B, Derakhshan A, Fini JB, Frädrich C, Hamers T, Hellwig L, Köhrle J, Korevaar TIM, Lindberg J, Martin O, Meima ME, Mergenthaler P, Nikolov N, Du Pasquier D, Peeters RP, Platzack B, Ramhøj L, Remaud S, Renko K, Scholze M, Stachelscheid H, Svingen T, Wagenaars F, Wedebye EB, and Zoeller RT
- Subjects
- Animals, Blood-Brain Barrier metabolism, Brain drug effects, Brain growth & development, Drug Discovery, Endocrine Disruptors chemistry, Humans, In Vitro Techniques, Internet, Endocrine Disruptors toxicity, High-Throughput Screening Assays methods, Thyroid Hormones metabolism
- Abstract
The test methods that currently exist for the identification of thyroid hormone system-disrupting chemicals are woefully inadequate. There are currently no internationally validated in vitro assays, and test methods that can capture the consequences of diminished or enhanced thyroid hormone action on the developing brain are missing entirely. These gaps put the public at risk and risk assessors in a difficult position. Decisions about the status of chemicals as thyroid hormone system disruptors currently are based on inadequate toxicity data. The ATHENA project (Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategies) has been conceived to address these gaps. The project will develop new test methods for the disruption of thyroid hormone transport across biological barriers such as the blood-brain and blood-placenta barriers. It will also devise methods for the disruption of the downstream effects on the brain. ATHENA will deliver a testing strategy based on those elements of the thyroid hormone system that, when disrupted, could have the greatest impact on diminished or enhanced thyroid hormone action and therefore should be targeted through effective testing. To further enhance the impact of the ATHENA test method developments, the project will develop concepts for better international collaboration and development in the area of thyroid hormone system disruptor identification and regulation.
- Published
- 2020
- Full Text
- View/download PDF
209. Impacts of food contact chemicals on human health: a consensus statement.
- Author
-
Muncke J, Andersson AM, Backhaus T, Boucher JM, Carney Almroth B, Castillo Castillo A, Chevrier J, Demeneix BA, Emmanuel JA, Fini JB, Gee D, Geueke B, Groh K, Heindel JJ, Houlihan J, Kassotis CD, Kwiatkowski CF, Lefferts LY, Maffini MV, Martin OV, Myers JP, Nadal A, Nerin C, Pelch KE, Fernández SR, Sargis RM, Soto AM, Trasande L, Vandenberg LN, Wagner M, Wu C, Zoeller RT, and Scheringer M
- Subjects
- Hazardous Substances adverse effects, Humans, Plastics adverse effects, Food Contamination analysis, Food Packaging methods
- Abstract
Food packaging is of high societal value because it conserves and protects food, makes food transportable and conveys information to consumers. It is also relevant for marketing, which is of economic significance. Other types of food contact articles, such as storage containers, processing equipment and filling lines, are also important for food production and food supply. Food contact articles are made up of one or multiple different food contact materials and consist of food contact chemicals. However, food contact chemicals transfer from all types of food contact materials and articles into food and, consequently, are taken up by humans. Here we highlight topics of concern based on scientific findings showing that food contact materials and articles are a relevant exposure pathway for known hazardous substances as well as for a plethora of toxicologically uncharacterized chemicals, both intentionally and non-intentionally added. We describe areas of certainty, like the fact that chemicals migrate from food contact articles into food, and uncertainty, for example unidentified chemicals migrating into food. Current safety assessment of food contact chemicals is ineffective at protecting human health. In addition, society is striving for waste reduction with a focus on food packaging. As a result, solutions are being developed toward reuse, recycling or alternative (non-plastic) materials. However, the critical aspect of chemical safety is often ignored. Developing solutions for improving the safety of food contact chemicals and for tackling the circular economy must include current scientific knowledge. This cannot be done in isolation but must include all relevant experts and stakeholders. Therefore, we provide an overview of areas of concern and related activities that will improve the safety of food contact articles and support a circular economy. Our aim is to initiate a broader discussion involving scientists with relevant expertise but not currently working on food contact materials, and decision makers and influencers addressing single-use food packaging due to environmental concerns. Ultimately, we aim to support science-based decision making in the interest of improving public health. Notably, reducing exposure to hazardous food contact chemicals contributes to the prevention of associated chronic diseases in the human population.
- Published
- 2020
- Full Text
- View/download PDF
210. Comparative Analyses of the 12 Most Abundant PCB Congeners Detected in Human Maternal Serum for Activity at the Thyroid Hormone Receptor and Ryanodine Receptor.
- Author
-
Sethi S, Morgan RK, Feng W, Lin Y, Li X, Luna C, Koch M, Bansal R, Duffel MW, Puschner B, Zoeller RT, Lehmler HJ, Pessah IN, and Lein PJ
- Subjects
- Child, Female, Humans, Pregnancy, Receptors, Thyroid Hormone, Ryanodine Receptor Calcium Release Channel, Serum, Environmental Pollutants, Polychlorinated Biphenyls
- Abstract
Polychlorinated biphenyls (PCBs) pose significant risk to the developing human brain; however, mechanisms of PCB developmental neurotoxicity (DNT) remain controversial. Two widely posited mechanisms are tested here using PCBs identified in pregnant women in the MARBLES cohort who are at increased risk for having a child with a neurodevelopmental disorder (NDD). As determined by gas chromatography-triple quadruple mass spectrometry, the mean PCB level in maternal serum was 2.22 ng/mL. The 12 most abundant PCBs were tested singly and as a mixture mimicking the congener profile in maternal serum for activity at the thyroid hormone receptor (THR) and ryanodine receptor (RyR). Neither the mixture nor the individual congeners (2 fM to 2 μM) exhibited agonistic or antagonistic activity in a THR reporter cell line. However, as determined by equilibrium binding of [
3 H]ryanodine to RyR1-enriched microsomes, the mixture and the individual congeners (50 nM to 50 μM) increased RyR activity by 2.4-19.2-fold. 4-Hydroxy (OH) and 4-sulfate metabolites of PCBs 11 and 52 had no TH activity; but 4-OH PCB 52 had higher potency than the parent congener toward RyR. These data support evidence implicating RyRs as targets in environmentally triggered NDDs and suggest that PCB effects on the THR are not a predominant mechanism driving PCB DNT. These findings provide scientific rationale regarding a point of departure for quantitative risk assessment of PCB DNT, and identify in vitro assays for screening other environmental pollutants for DNT potential.- Published
- 2019
- Full Text
- View/download PDF
211. Correction to: Parma consensus statement on metabolic disruptors.
- Author
-
Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, Cohn BA, Fabbri E, Gioiosa L, Kassotis C, Legler J, La Merrill M, Rizzi L, Machtinger R, Mantovani A, Mendez MA, Montanini L, Molteni L, Nagel SC, Parmigiani S, Panzica G, Paterlini S, Pomatto V, Ruzzin J, Sartor G, Schug TT, Street ME, Suvorov A, Volpi R, Zoeller RT, and Palanza P
- Abstract
Correction: After publication of the article [1], it has been brought to our attention that the thirteenth author of this article has had their name spelt incorrectly. In the original article the spelling "Laura Rizzir" was used. In fact the correct spelling should be "Laura Rizzi".
- Published
- 2017
- Full Text
- View/download PDF
212. Effects of Sample Handling and Analytical Procedures on Thyroid Hormone Concentrations in Pregnant Women's Plasma.
- Author
-
Villanger GD, Learner E, Longnecker MP, Ask H, Aase H, Zoeller RT, Knudsen GP, Reichborn-Kjennerud T, Zeiner P, and Engel SM
- Subjects
- Adult, Autoantibodies immunology, Autoantigens immunology, Cryopreservation, Female, Humans, Iodide Peroxidase immunology, Iron-Binding Proteins immunology, Plasma, Reproducibility of Results, Serum, Pregnancy blood, Specimen Handling methods, Thyrotropin blood, Thyroxine blood, Triiodothyronine blood
- Abstract
Background: Maternal thyroid function is a critical mediator of fetal brain development. Pregnancy-related physiologic changes and handling conditions of blood samples may influence thyroid hormone biomarkers. We investigated the reliability of thyroid hormone biomarkers in plasma of pregnant women under various handling conditions., Methods: We enrolled 17 pregnant women; collected serum and plasma were immediately frozen. Additional plasma aliquots were subjected to different handling conditions before the analysis of thyroid biomarkers: storage at room temperature for 24 or 48 hours before freezing and an extra freeze-thaw cycle. We estimated free thyroid hormone indices in plasma based on T3 uptake., Results: High correlations between plasma and serum (>0.94) and intraclass correlation coefficients for plasma handling conditions (0.96 to 1.00) indicated excellent reliability for all thyroid hormone biomarkers., Conclusion: Delayed freezing and freeze-thaw cycles did not affect reliability of biomarkers of thyroid function in plasma during pregnancy. See video abstract at, http://links.lww.com/EDE/B180.
- Published
- 2017
- Full Text
- View/download PDF
213. Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement.
- Author
-
Solecki R, Kortenkamp A, Bergman Å, Chahoud I, Degen GH, Dietrich D, Greim H, Håkansson H, Hass U, Husoy T, Jacobs M, Jobling S, Mantovani A, Marx-Stoelting P, Piersma A, Ritz V, Slama R, Stahlmann R, van den Berg M, Zoeller RT, and Boobis AR
- Subjects
- Animals, European Union, Government Regulation, Humans, Risk Assessment legislation & jurisprudence, Ecotoxicology legislation & jurisprudence, Endocrine Disruptors toxicity
- Abstract
Endocrine disruption is a specific form of toxicity, where natural and/or anthropogenic chemicals, known as "endocrine disruptors" (EDs), trigger adverse health effects by disrupting the endogenous hormone system. There is need to harmonize guidance on the regulation of EDs, but this has been hampered by what appeared as a lack of consensus among scientists. This publication provides summary information about a consensus reached by a group of world-leading scientists that can serve as the basis for the development of ED criteria in relevant EU legislation. Twenty-three international scientists from different disciplines discussed principles and open questions on ED identification as outlined in a draft consensus paper at an expert meeting hosted by the German Federal Institute for Risk Assessment (BfR) in Berlin, Germany on 11-12 April 2016. Participants reached a consensus regarding scientific principles for the identification of EDs. The paper discusses the consensus reached on background, definition of an ED and related concepts, sources of uncertainty, scientific principles important for ED identification, and research needs. It highlights the difficulty in retrospectively reconstructing ED exposure, insufficient range of validated test systems for EDs, and some issues impacting on the evaluation of the risk from EDs, such as non-monotonic dose-response and thresholds, modes of action, and exposure assessment. This report provides the consensus statement on EDs agreed among all participating scientists. The meeting facilitated a productive debate and reduced a number of differences in views. It is expected that the consensus reached will serve as an important basis for the development of regulatory ED criteria.
- Published
- 2017
- Full Text
- View/download PDF
214. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis.
- Author
-
Attina TM, Hauser R, Sathyanarayana S, Hunt PA, Bourguignon JP, Myers JP, DiGangi J, Zoeller RT, and Trasande L
- Subjects
- Animals, Cost of Illness, Costs and Cost Analysis, Humans, United States, Endocrine Disruptors economics, Environmental Exposure economics
- Abstract
Background: Endocrine-disrupting chemicals (EDCs) contribute to disease and dysfunction and incur high associated costs (>1% of the gross domestic product [GDP] in the European Union). Exposure to EDCs varies widely between the USA and Europe because of differences in regulations and, therefore, we aimed to quantify disease burdens and related economic costs to allow comparison., Methods: We used existing models for assessing epidemiological and toxicological studies to reach consensus on probabilities of causation for 15 exposure-response relations between substances and disorders. We used Monte Carlo methods to produce realistic probability ranges for costs across the exposure-response relation, taking into account uncertainties. Estimates were made based on population and costs in the USA in 2010. Costs for the European Union were converted to US$ (€1=$1·33)., Findings: The disease costs of EDCs were much higher in the USA than in Europe ($340 billion [2·33% of GDP] vs $217 billion [1·28%]). The difference was driven mainly by intelligence quotient (IQ) points loss and intellectual disability due to polybrominated diphenyl ethers (11 million IQ points lost and 43 000 cases costing $266 billion in the USA vs 873 000 IQ points lost and 3290 cases costing $12·6 billion in the European Union). Accounting for probability of causation, in the European Union, organophosphate pesticides were the largest contributor to costs associated with EDC exposure ($121 billion), whereas in the USA costs due to pesticides were much lower ($42 billion)., Interpretation: EDC exposure in the USA contributes to disease and dysfunction, with annual costs taking up more than 2% of the GDP. Differences from the European Union suggest the need for improved screening for chemical disruption to endocrine systems and proactive prevention., Funding: Endocrine Society, Ralph S French Charitable Foundation, and Broad Reach Foundation., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
215. Project TENDR: Targeting Environmental Neuro-Developmental Risks The TENDR Consensus Statement.
- Author
-
Bennett D, Bellinger DC, Birnbaum LS, Bradman A, Chen A, Cory-Slechta DA, Engel SM, Fallin MD, Halladay A, Hauser R, Hertz-Picciotto I, Kwiatkowski CF, Lanphear BP, Marquez E, Marty M, McPartland J, Newschaffer CJ, Payne-Sturges D, Patisaul HB, Perera FP, Ritz B, Sass J, Schantz SL, Webster TF, Whyatt RM, Woodruff TJ, Zoeller RT, Anderko L, Campbell C, Conry JA, DeNicola N, Gould RM, Hirtz D, Huffling K, Landrigan PJ, Lavin A, Miller M, Mitchell MA, Rubin L, Schettler T, Tran HL, Acosta A, Brody C, Miller E, Miller P, Swanson M, and Witherspoon NO
- Subjects
- Child, Humans, Risk Assessment methods, United States, Developmental Disabilities prevention & control, Environmental Exposure prevention & control, Environmental Health methods, Neurodevelopmental Disorders prevention & control, Public Health methods
- Published
- 2016
- Full Text
- View/download PDF
216. Endocrine-Disrupting Activity of Hydraulic Fracturing Chemicals and Adverse Health Outcomes After Prenatal Exposure in Male Mice.
- Author
-
Kassotis CD, Klemp KC, Vu DC, Lin CH, Meng CX, Besch-Williford CL, Pinatti L, Zoeller RT, Drobnis EZ, Balise VD, Isiguzo CJ, Williams MA, Tillitt DE, and Nagel SC
- Subjects
- Animals, Female, Male, Mice, Organ Size, Pregnancy, Receptors, Androgen drug effects, Receptors, Estrogen drug effects, Receptors, Glucocorticoid drug effects, Receptors, Progesterone drug effects, Receptors, Thyroid Hormone drug effects, Sperm Count, Sperm Motility drug effects, Testis pathology, Testosterone blood, Body Weight drug effects, Endocrine Disruptors pharmacology, Hydraulic Fracking, Prenatal Exposure Delayed Effects, Spermatozoa drug effects, Testis drug effects, Wastewater chemistry
- Abstract
Oil and natural gas operations have been shown to contaminate surface and ground water with endocrine-disrupting chemicals. In the current study, we fill several gaps in our understanding of the potential environmental impacts related to this process. We measured the endocrine-disrupting activities of 24 chemicals used and/or produced by oil and gas operations for five nuclear receptors using a reporter gene assay in human endometrial cancer cells. We also quantified the concentration of 16 of these chemicals in oil and gas wastewater samples. Finally, we assessed reproductive and developmental outcomes in male C57BL/6J mice after the prenatal exposure to a mixture of these chemicals. We found that 23 commonly used oil and natural gas operation chemicals can activate or inhibit the estrogen, androgen, glucocorticoid, progesterone, and/or thyroid receptors, and mixtures of these chemicals can behave synergistically, additively, or antagonistically in vitro. Prenatal exposure to a mixture of 23 oil and gas operation chemicals at 3, 30, and 300 μg/kg · d caused decreased sperm counts and increased testes, body, heart, and thymus weights and increased serum testosterone in male mice, suggesting multiple organ system impacts. Our results suggest possible adverse developmental and reproductive health outcomes in humans and animals exposed to potential environmentally relevant levels of oil and gas operation chemicals.
- Published
- 2015
- Full Text
- View/download PDF
217. Manufacturing doubt about endocrine disrupter science--A rebuttal of industry-sponsored critical comments on the UNEP/WHO report "State of the Science of Endocrine Disrupting Chemicals 2012".
- Author
-
Bergman Å, Becher G, Blumberg B, Bjerregaard P, Bornman R, Brandt I, Casey SC, Frouin H, Giudice LC, Heindel JJ, Iguchi T, Jobling S, Kidd KA, Kortenkamp A, Lind PM, Muir D, Ochieng R, Ropstad E, Ross PS, Skakkebaek NE, Toppari J, Vandenberg LN, Woodruff TJ, and Zoeller RT
- Subjects
- Animals, Humans, Endocrine Disruptors toxicity
- Abstract
We present a detailed response to the critique of "State of the Science of Endocrine Disrupting Chemicals 2012" (UNEP/WHO, 2013) by financial stakeholders, authored by Lamb et al. (2014). Lamb et al.'s claim that UNEP/WHO (2013) does not provide a balanced perspective on endocrine disruption is based on incomplete and misleading quoting of the report through omission of qualifying statements and inaccurate description of study objectives, results and conclusions. Lamb et al. define extremely narrow standards for synthesizing evidence which are then used to dismiss the UNEP/WHO 2013 report as flawed. We show that Lamb et al. misuse conceptual frameworks for assessing causality, especially the Bradford-Hill criteria, by ignoring the fundamental problems that exist with inferring causality from empirical observations. We conclude that Lamb et al.'s attempt of deconstructing the UNEP/WHO (2013) report is not particularly erudite and that their critique is not intended to be convincing to the scientific community, but to confuse the scientific data. Consequently, it promotes misinterpretation of the UNEP/WHO (2013) report by non-specialists, bureaucrats, politicians and other decision makers not intimately familiar with the topic of endocrine disruption and therefore susceptible to false generalizations of bias and subjectivity., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
218. Parma consensus statement on metabolic disruptors.
- Author
-
Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, Cohn BA, Fabbri E, Gioiosa L, Kassotis C, Legler J, La Merrill M, Rizzir L, Machtinger R, Mantovani A, Mendez MA, Montanini L, Molteni L, Nagel SC, Parmigiani S, Panzica G, Paterlini S, Pomatto V, Ruzzin J, Sartor G, Schug TT, Street ME, Suvorov A, Volpi R, Zoeller RT, and Palanza P
- Subjects
- Congresses as Topic, Diabetes Mellitus chemically induced, Humans, Italy, Metabolic Syndrome chemically induced, Obesity chemically induced, Consensus Development Conferences as Topic, Environmental Exposure adverse effects, Environmental Pollutants adverse effects, Hazardous Substances adverse effects
- Abstract
A multidisciplinary group of experts gathered in Parma Italy for a workshop hosted by the University of Parma, May 16-18, 2014 to address concerns about the potential relationship between environmental metabolic disrupting chemicals, obesity and related metabolic disorders. The objectives of the workshop were to: 1. Review findings related to the role of environmental chemicals, referred to as "metabolic disruptors", in obesity and metabolic syndrome with special attention to recent discoveries from animal model and epidemiology studies; 2. Identify conclusions that could be drawn with confidence from existing animal and human data; 3. Develop predictions based on current data; and 4. Identify critical knowledge gaps and areas of uncertainty. The consensus statements are intended to aid in expanding understanding of the role of metabolic disruptors in the obesity and metabolic disease epidemics, to move the field forward by assessing the current state of the science and to identify research needs on the role of environmental chemical exposures in these diseases. We propose broadening the definition of obesogens to that of metabolic disruptors, to encompass chemicals that play a role in altered susceptibility to obesity, diabetes and related metabolic disorders including metabolic syndrome.
- Published
- 2015
- Full Text
- View/download PDF
219. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
- Author
-
Bellanger M, Demeneix B, Grandjean P, Zoeller RT, and Trasande L
- Subjects
- Adolescent, Adult, Attention Deficit Disorder with Hyperactivity chemically induced, Attention Deficit Disorder with Hyperactivity economics, Attention Deficit Disorder with Hyperactivity epidemiology, Autistic Disorder chemically induced, Autistic Disorder economics, Autistic Disorder epidemiology, Child, Child, Preschool, Endocrine System Diseases chemically induced, Endocrine System Diseases epidemiology, Environmental Exposure statistics & numerical data, Europe epidemiology, European Union statistics & numerical data, Female, Humans, Intellectual Disability chemically induced, Intellectual Disability economics, Intellectual Disability epidemiology, Male, Mental Disorders chemically induced, Mental Disorders epidemiology, Cost of Illness, Endocrine Disruptors toxicity, Endocrine System Diseases economics, Environmental Exposure economics, European Union economics, Mental Disorders economics
- Abstract
Context: Epidemiological studies and animal models demonstrate that endocrine-disrupting chemicals (EDCs) contribute to cognitive deficits and neurodevelopmental disabilities., Objective: The objective was to estimate neurodevelopmental disability and associated costs that can be reasonably attributed to EDC exposure in the European Union., Design: An expert panel applied a weight-of-evidence characterization adapted from the Intergovernmental Panel on Climate Change. Exposure-response relationships and reference levels were evaluated for relevant EDCs, and biomarker data were organized from peer-reviewed studies to represent European exposure and approximate burden of disease. Cost estimation as of 2010 utilized lifetime economic productivity estimates, lifetime cost estimates for autism spectrum disorder, and annual costs for attention-deficit hyperactivity disorder. Setting, Patients and Participants, and Intervention: Cost estimation was carried out from a societal perspective, ie, including direct costs (eg, treatment costs) and indirect costs such as productivity loss., Results: The panel identified a 70-100% probability that polybrominated diphenyl ether and organophosphate exposures contribute to IQ loss in the European population. Polybrominated diphenyl ether exposures were associated with 873,000 (sensitivity analysis, 148,000 to 2.02 million) lost IQ points and 3290 (sensitivity analysis, 3290 to 8080) cases of intellectual disability, at costs of €9.59 billion (sensitivity analysis, €1.58 billion to €22.4 billion). Organophosphate exposures were associated with 13.0 million (sensitivity analysis, 4.24 million to 17.1 million) lost IQ points and 59 300 (sensitivity analysis, 16,500 to 84,400) cases of intellectual disability, at costs of €146 billion (sensitivity analysis, €46.8 billion to €194 billion). Autism spectrum disorder causation by multiple EDCs was assigned a 20-39% probability, with 316 (sensitivity analysis, 126-631) attributable cases at a cost of €199 million (sensitivity analysis, €79.7 million to €399 million). Attention-deficit hyperactivity disorder causation by multiple EDCs was assigned a 20-69% probability, with 19 300 to 31 200 attributable cases at a cost of €1.21 billion to €2.86 billion., Conclusions: EDC exposures in Europe contribute substantially to neurobehavioral deficits and disease, with a high probability of >€150 billion costs/year. These results emphasize the advantages of controlling EDC exposure.
- Published
- 2015
- Full Text
- View/download PDF
220. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.
- Author
-
Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Bellanger M, Hauser R, Legler J, Skakkebaek NE, and Heindel JJ
- Subjects
- Adult, Aged, Attention Deficit Disorder with Hyperactivity chemically induced, Attention Deficit Disorder with Hyperactivity economics, Attention Deficit Disorder with Hyperactivity epidemiology, Autistic Disorder chemically induced, Autistic Disorder economics, Autistic Disorder epidemiology, Child, Endocrine System Diseases epidemiology, Environmental Exposure statistics & numerical data, Environmental Pollutants toxicity, European Union statistics & numerical data, Female, Humans, Male, Middle Aged, Cost of Illness, Endocrine Disruptors toxicity, Endocrine System Diseases economics, Environmental Exposure economics, European Union economics
- Abstract
Context: Rapidly increasing evidence has documented that endocrine-disrupting chemicals (EDCs) contribute substantially to disease and disability., Objective: The objective was to quantify a range of health and economic costs that can be reasonably attributed to EDC exposures in the European Union (EU)., Design: A Steering Committee of scientists adapted the Intergovernmental Panel on Climate Change weight-of-evidence characterization for probability of causation based upon levels of available epidemiological and toxicological evidence for one or more chemicals contributing to disease by an endocrine disruptor mechanism. To evaluate the epidemiological evidence, the Steering Committee adapted the World Health Organization Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group criteria, whereas the Steering Committee adapted definitions recently promulgated by the Danish Environmental Protection Agency for evaluating laboratory and animal evidence of endocrine disruption. Expert panels used the Delphi method to make decisions on the strength of the data., Results: Expert panels achieved consensus at least for probable (>20%) EDC causation for IQ loss and associated intellectual disability, autism, attention-deficit hyperactivity disorder, childhood obesity, adult obesity, adult diabetes, cryptorchidism, male infertility, and mortality associated with reduced testosterone. Accounting for probability of causation and using the midpoint of each range for probability of causation, Monte Carlo simulations produced a median cost of €157 billion (or $209 billion, corresponding to 1.23% of EU gross domestic product) annually across 1000 simulations. Notably, using the lowest end of the probability range for each relationship in the Monte Carlo simulations produced a median range of €109 billion that differed modestly from base case probability inputs., Conclusions: EDC exposures in the EU are likely to contribute substantially to disease and dysfunction across the life course with costs in the hundreds of billions of Euros per year. These estimates represent only those EDCs with the highest probability of causation; a broader analysis would have produced greater estimates of burden of disease and costs.
- Published
- 2015
- Full Text
- View/download PDF
221. Endocrine disruption in human placenta: expression of the dioxin-inducible enzyme, CYP1A1, is correlated with that of thyroid hormone-regulated genes.
- Author
-
Wadzinski TL, Geromini K, McKinley Brewer J, Bansal R, Abdelouahab N, Langlois MF, Takser L, and Zoeller RT
- Subjects
- Adult, Cell Line, Dioxins, Female, Fetal Blood chemistry, Human Growth Hormone blood, Humans, Placenta drug effects, Placental Lactogen blood, Pregnancy, Smoking genetics, Thyroid Hormones metabolism, Cytochrome P-450 CYP1A1 biosynthesis, Endocrine Disruptors pharmacology, Gene Expression Regulation, Enzymologic genetics, Gene Expression Regulation, Enzymologic physiology, Placenta enzymology, Thyroid Hormones physiology
- Abstract
Context: Thyroid hormone (TH) is essential for normal development; therefore, disruption of TH action by a number of industrial chemicals is critical to identify. Several chemicals including polychlorinated biphenyls are metabolized by the dioxin-inducible enzyme CYP1A1; some of their metabolites can interact with the TH receptor. In animals, this mechanism is reflected by a strong correlation between the expression of CYP1A1 mRNA and TH-regulated mRNAs. If this mechanism occurs in humans, we expect that CYP1A1 expression will be positively correlated with the expression of genes regulated by TH., Objective: The objective of the study was to test the hypothesis that CYP1A1 mRNA expression is correlated with TH-regulated mRNAs in human placenta., Methods: One hundred sixty-four placental samples from pregnancies with no thyroid disease were obtained from the GESTE study (Sherbrooke, Québec, Canada). Maternal and cord blood TH levels were measured at birth. The mRNA levels of CYP1A1 and placental TH receptor targets [placental lactogen (PL) and GH-V] were quantitated by quantitative PCR., Results: CYP1A1 mRNA abundance varied 5-fold across 132 placental samples that had detectable CYP1A1 mRNA. CYP1A1 mRNA was positively correlated with PL (r = 0.64; P < .0001) and GH-V (P < .0001, r = 0.62) mRNA. PL and GH-V mRNA were correlated with each other (r = 0.95; P < .0001), suggesting a common activator. The mRNAs not regulated by TH were not correlated with CYP1A1 expression., Conclusions: CYP1A1 mRNA expression is strongly associated with the expression of TH-regulated target gene mRNAs in human placenta, consistent with the endocrine-disrupting action of metabolites produced by CYP1A1.
- Published
- 2014
- Full Text
- View/download PDF
222. Polybrominated diphenyl ether (DE-71) interferes with thyroid hormone action independent of effects on circulating levels of thyroid hormone in male rats.
- Author
-
Bansal R, Tighe D, Danai A, Rawn DF, Gaertner DW, Arnold DL, Gilbert ME, and Zoeller RT
- Subjects
- Animals, Animals, Newborn, Female, Male, Maternal Exposure, Pregnancy, Propylthiouracil pharmacology, Rats, Rats, Sprague-Dawley, Sex Factors, Thyroid Function Tests, Antithyroid Agents pharmacology, Endocrine Disruptors pharmacology, Halogenated Diphenyl Ethers pharmacology, Thyroid Gland drug effects, Thyroid Gland physiology, Thyroid Hormones blood
- Abstract
Polybrominated diphenyl ethers (PBDEs) are routinely found in human tissues including cord blood and breast milk. PBDEs may interfere with thyroid hormone (TH) during development, which could produce neurobehavioral deficits. An assumption in experimental and epidemiological studies is that PBDE effects on serum TH levels will reflect PBDE effects on TH action in tissues. To test whether this assumption is correct, we performed the following experiments. First, five concentrations of diphenyl ether (0-30 mg/kg) were fed daily to pregnant rats to postnatal day 21. PBDEs were measured in dam liver and heart to estimate internal dose. The results were compared with a separate study in which four concentrations of propylthiouracil (PTU; 0, 1, 2, and 3 ppm) was provided to pregnant rats in drinking water for the same duration as for diphenyl ether. PBDE exposure reduced serum T4 similar in magnitude to PTU, but serum TSH was not elevated by PBDE. PBDE treatment did not affect the expression of TH response genes in the liver or heart as did PTU treatment. PTU treatment reduced T4 in liver and heart, but PBDE treatment reduced T4 only in the heart. Tissue PBDEs were in the micrograms per gram lipid range, only slightly higher than observed in human fetal tissues. Thus, PBDE exposure reduces serum T4 but does not produce effects on tissues typical of low TH produced by PTU, demonstrating that the effects of chemical exposure on serum T4 levels may not always be a faithful proxy measure of chemical effects on the ability of thyroid hormone to regulate development and adult physiology.
- Published
- 2014
- Full Text
- View/download PDF
223. Regulation of endocrine-disrupting chemicals insufficient to safeguard public health.
- Author
-
Zoeller RT
- Subjects
- Female, Humans, Body Mass Index, Environmental Pollutants blood, Obesity metabolism, Organic Chemicals blood
- Published
- 2014
- Full Text
- View/download PDF
224. Temporal comparison of PBDEs, OH-PBDEs, PCBs, and OH-PCBs in the serum of second trimester pregnant women recruited from San Francisco General Hospital, California.
- Author
-
Zota AR, Linderholm L, Park JS, Petreas M, Guo T, Privalsky ML, Zoeller RT, and Woodruff TJ
- Subjects
- Adolescent, Adult, Cohort Studies, Demography, Female, Humans, Least-Squares Analysis, Maternal Age, Multivariate Analysis, Pregnancy, San Francisco, Time Factors, Young Adult, Halogenated Diphenyl Ethers blood, Hospitals, General, Polychlorinated Biphenyls blood, Pregnancy Trimester, Second blood
- Abstract
Prenatal exposures to polybrominated diphenyl ethers (PBDEs) can harm neurodevelopment in humans and animals. In 2003-2004, PentaBDE and OctaBDE were banned in California and phased-out of US production; resulting impacts on human exposures are unknown. We previously reported that median serum concentrations of PBDEs and their metabolites (OH-PBDEs) among second trimester pregnant women recruited from San Francisco General Hospital (2008-2009; n = 25) were the highest among pregnant women worldwide. We recruited another cohort from the same clinic in 2011-2012 (n = 36) and now compare serum concentrations of PBDEs, OH-PBDEs, polychlorinated biphenyl ethers (PCBs) (structurally similar compounds banned in 1979), and OH-PCBs between two demographically similar cohorts. Between 2008-2009 and 2011-2012, adjusted least-squares geometric mean (LSGM) concentrations of ∑PBDEs decreased 65% (95% CI: 18, 130) from 90.0 ng/g lipid (95% CI: 64.7, 125.2) to 54.6 ng/g lipid (95% CI: 39.2, 76.2) (p = 0.004); ∑OH-PBDEs decreased 6-fold (p < 0.0001); and BDE-47, -99, and -100 declined more than BDE-153. There was a modest, nonsignificant (p = 0.13) decline in LSGM concentrations of ∑PCBs and minimal differences in ∑OH-PCBs between 2008-2009 and 2011-2012. PBDE exposures are likely declining due to regulatory action, but the relative stability in PCB exposures suggests PBDE exposures may eventually plateau and persist for decades.
- Published
- 2013
- Full Text
- View/download PDF
225. Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society.
- Author
-
Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff TJ, and Vom Saal FS
- Subjects
- Humans, Endocrine Disruptors standards, Endocrine Disruptors toxicity, Public Health standards, Societies, Medical
- Abstract
An endocrine-disrupting chemical (EDC) is an exogenous chemical, or mixture of chemicals, that can interfere with any aspect of hormone action. The potential for deleterious effects of EDC must be considered relative to the regulation of hormone synthesis, secretion, and actions and the variability in regulation of these events across the life cycle. The developmental age at which EDC exposures occur is a critical consideration in understanding their effects. Because endocrine systems exhibit tissue-, cell-, and receptor-specific actions during the life cycle, EDC can produce complex, mosaic effects. This complexity causes difficulty when a static approach to toxicity through endocrine mechanisms driven by rigid guidelines is used to identify EDC and manage risk to human and wildlife populations. We propose that principles taken from fundamental endocrinology be employed to identify EDC and manage their risk to exposed populations. We emphasize the importance of developmental stage and, in particular, the realization that exposure to a presumptive "safe" dose of chemical may impact a life stage when there is normally no endogenous hormone exposure, thereby underscoring the potential for very low-dose EDC exposures to have potent and irreversible effects. Finally, with regard to the current program designed to detect putative EDC, namely, the Endocrine Disruptor Screening Program, we offer recommendations for strengthening this program through the incorporation of basic endocrine principles to promote further understanding of complex EDC effects, especially due to developmental exposures.
- Published
- 2012
- Full Text
- View/download PDF
226. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.
- Author
-
Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, Shioda T, Soto AM, vom Saal FS, Welshons WV, Zoeller RT, and Myers JP
- Subjects
- Amphibians growth & development, Animals, Animals, Wild, Atrazine toxicity, Benzhydryl Compounds, Dioxins toxicity, Dose-Response Relationship, Drug, Environmental Exposure, Female, Herbicides toxicity, Humans, Male, Perchlorates toxicity, Phenols toxicity, Prostate drug effects, Sexual Development drug effects, Spermatogenesis drug effects, Thyroid Gland drug effects, Twins, Breast drug effects, Endocrine Disruptors toxicity
- Abstract
For decades, studies of endocrine-disrupting chemicals (EDCs) have challenged traditional concepts in toxicology, in particular the dogma of "the dose makes the poison," because EDCs can have effects at low doses that are not predicted by effects at higher doses. Here, we review two major concepts in EDC studies: low dose and nonmonotonicity. Low-dose effects were defined by the National Toxicology Program as those that occur in the range of human exposures or effects observed at doses below those used for traditional toxicological studies. We review the mechanistic data for low-dose effects and use a weight-of-evidence approach to analyze five examples from the EDC literature. Additionally, we explore nonmonotonic dose-response curves, defined as a nonlinear relationship between dose and effect where the slope of the curve changes sign somewhere within the range of doses examined. We provide a detailed discussion of the mechanisms responsible for generating these phenomena, plus hundreds of examples from the cell culture, animal, and epidemiology literature. We illustrate that nonmonotonic responses and low-dose effects are remarkably common in studies of natural hormones and EDCs. Whether low doses of EDCs influence certain human disorders is no longer conjecture, because epidemiological studies show that environmental exposures to EDCs are associated with human diseases and disabilities. We conclude that when nonmonotonic dose-response curves occur, the effects of low doses cannot be predicted by the effects observed at high doses. Thus, fundamental changes in chemical testing and safety determination are needed to protect human health.
- Published
- 2012
- Full Text
- View/download PDF
227. Individual polychlorinated biphenyl (PCB) congeners produce tissue- and gene-specific effects on thyroid hormone signaling during development.
- Author
-
Giera S, Bansal R, Ortiz-Toro TM, Taub DG, and Zoeller RT
- Subjects
- Animals, Antithyroid Agents chemistry, Cytochrome P-450 CYP1A1 biosynthesis, Cytochrome P-450 CYP1A1 genetics, Environmental Pollutants chemistry, Enzyme Induction drug effects, Female, Lactation, Male, Nuclear Proteins biosynthesis, Nuclear Proteins genetics, Organ Specificity, Polychlorinated Biphenyls chemistry, Polychlorinated Biphenyls metabolism, Pregnancy, Prenatal Exposure Delayed Effects blood, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Thyroid Hormones blood, Transcription Factors biosynthesis, Transcription Factors genetics, Antithyroid Agents toxicity, Environmental Pollutants toxicity, Gene Expression Regulation drug effects, Polychlorinated Biphenyls toxicity, Prenatal Exposure Delayed Effects metabolism, Receptors, Thyroid Hormone antagonists & inhibitors, Signal Transduction drug effects
- Abstract
Polychlorinated biphenyls (PCB) are industrial chemicals linked to developmental deficits that may be caused in part by disrupting thyroid hormone (TH) action by either reducing serum TH or interacting directly with the TH receptor (TR). Individual PCB congeners can activate the TR in vitro when the metabolic enzyme cytochrome P4501A1 (CYP1A1) is induced, suggesting that specific PCB metabolites act as TR agonists. To test this hypothesis in vivo, we compared two combinations of PCB congeners that either activate the TR (PCB 105 and 118) or not (PCB 138 and 153) in the presence or absence of a PCB congener (PCB 126) that induces CYP1A1 in vitro. Aroclor 1254 was used as a positive control, and a group treated with propylthiouracil was included to characterize the effects of low serum TH. We monitored the effects on TH signaling in several peripheral tissues by measuring the mRNA expression of well-known TH-response genes in these tissues. Aroclor 1254 and its component PCB 105/118/126 reduced total T(4) to the same extent as that of propylthiouracil but increased the expression of some TH target genes in liver. This effect was strongly correlated with CYP1A1 expression supporting the hypothesis that metabolism is necessary. Effects were gene and tissue specific, indicating that tissue-specific metabolism is an important component of PCB disruption of TH action and that PCB metabolites interact in complex ways with the TR. These are essential mechanisms to consider when evaluating the health risks of contaminant exposures, for both PCB and other polycyclic compounds known to interact with nuclear hormone receptors.
- Published
- 2011
- Full Text
- View/download PDF
228. A clash of old and new scientific concepts in toxicity, with important implications for public health.
- Author
-
Myers JP, Zoeller RT, and vom Saal FS
- Subjects
- Animals, Dose-Response Relationship, Drug, Endocrine Disruptors administration & dosage, Forecasting, Humans, Public Health, Research Design, Endocrine Disruptors toxicity, Environmental Exposure adverse effects, Toxicity Tests methods
- Abstract
Background: A core assumption of current toxicologic procedures used to establish health standards for chemical exposures is that testing the safety of chemicals at high doses can be used to predict the effects of low-dose exposures, such as those common in the general population. This assumption is based on the precept that "the dose makes the poison": higher doses will cause greater effects., Objectives: We challenge the validity of assuming that high-dose testing can be used to predict low-dose effects for contaminants that behave like hormones. We review data from endocrinology and toxicology that falsify this assumption and summarize current mechanistic understanding of how low doses can lead to effects unpredictable from high-dose experiments., Discussion: Falsification of this assumption raises profound issues for regulatory toxicology. Many exposure standards are based on this assumption. Rejecting the assumption will require that these standards be reevaluated and that procedures employed to set health standards be changed. The consequences of these changes may be significant for public health because of the range of health conditions now plausibly linked to exposure to endocrine-disrupting contaminants., Conclusions: We recommend that procedures to establish acceptable exposure levels for endocrine-disrupting compounds incorporate the inability for high-dose tests to predict low-dose results. Setting acceptable levels of exposure must include testing for health consequences at prevalent levels of human exposure, not extrapolations from the effects observed in high-dose experiments. Scientists trained in endocrinology must be engaged systematically in standard setting for endocrine-disrupting compounds.
- Published
- 2009
- Full Text
- View/download PDF
229. Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A.
- Author
-
Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, Colborn T, Chahoud I, Crain DA, Farabollini F, Guillette LJ Jr, Hassold T, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Laufer H, Marcus M, McLachlan JA, Nadal A, Oehlmann J, Olea N, Palanza P, Parmigiani S, Rubin BS, Schoenfelder G, Sonnenschein C, Soto AM, Talsness CE, Taylor JA, Vandenberg LN, Vandenbergh JG, Vogel S, Watson CS, Welshons WV, and Zoeller RT
- Subjects
- Benzhydryl Compounds, Risk Assessment methods, Risk Assessment standards, Clinical Laboratory Techniques standards, Ecotoxicology methods, Ecotoxicology standards, Endocrine Disruptors toxicity, Phenols toxicity, Public Health Practice standards
- Abstract
Background: In their safety evaluations of bisphenol A (BPA), the U.S. Food and Drug Administration (FDA) and a counterpart in Europe, the European Food Safety Authority (EFSA), have given special prominence to two industry-funded studies that adhered to standards defined by Good Laboratory Practices (GLP). These same agencies have given much less weight in risk assessments to a large number of independently replicated non-GLP studies conducted with government funding by the leading experts in various fields of science from around the world., Objectives: We reviewed differences between industry-funded GLP studies of BPA conducted by commercial laboratories for regulatory purposes and non-GLP studies conducted in academic and government laboratories to identify hazards and molecular mechanisms mediating adverse effects. We examined the methods and results in the GLP studies that were pivotal in the draft decision of the U.S. FDA declaring BPA safe in relation to findings from studies that were competitive for U.S. National Institutes of Health (NIH) funding, peer-reviewed for publication in leading journals, subject to independent replication, but rejected by the U.S. FDA for regulatory purposes., Discussion: Although the U.S. FDA and EFSA have deemed two industry-funded GLP studies of BPA to be superior to hundreds of studies funded by the U.S. NIH and NIH counterparts in other countries, the GLP studies on which the agencies based their decisions have serious conceptual and methodologic flaws. In addition, the U.S. FDA and EFSA have mistakenly assumed that GLP yields valid and reliable scientific findings (i.e., "good science"). Their rationale for favoring GLP studies over hundreds of publically funded studies ignores the central factor in determining the reliability and validity of scientific findings, namely, independent replication, and use of the most appropriate and sensitive state-of-the-art assays, neither of which is an expectation of industry-funded GLP research., Conclusions: Public health decisions should be based on studies using appropriate protocols with appropriate controls and the most sensitive assays, not GLP. Relevant NIH-funded research using state-of-the-art techniques should play a prominent role in safety evaluations of chemicals.
- Published
- 2009
- Full Text
- View/download PDF
230. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making.
- Author
-
Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, Miller GG, Schwartz JM, Alexeeff G, Anderson H, Birnbaum L, Bois F, Cogliano VJ, Crofton K, Euling SY, Foster PM, Germolec DR, Gray E, Hattis DB, Kyle AD, Luebke RW, Luster MI, Portier C, Rice DC, Solomon G, Vandenberg J, and Zoeller RT
- Subjects
- Humans, Decision Making, Risk Assessment
- Abstract
Background: Assessing adverse effects from environmental chemical exposure is integral to public health policies. Toxicology assays identifying early biological changes from chemical exposure are increasing our ability to evaluate links between early biological disturbances and subsequent overt downstream effects. A workshop was held to consider how the resulting data inform consideration of an "adverse effect" in the context of hazard identification and risk assessment., Objectives: Our objective here is to review what is known about the relationships between chemical exposure, early biological effects (upstream events), and later overt effects (downstream events) through three case studies (thyroid hormone disruption, antiandrogen effects, immune system disruption) and to consider how to evaluate hazard and risk when early biological effect data are available., Discussion: Each case study presents data on the toxicity pathways linking early biological perturbations with downstream overt effects. Case studies also emphasize several factors that can influence risk of overt disease as a result from early biological perturbations, including background chemical exposures, underlying individual biological processes, and disease susceptibility. Certain effects resulting from exposure during periods of sensitivity may be irreversible. A chemical can act through multiple modes of action, resulting in similar or different overt effects., Conclusions: For certain classes of early perturbations, sufficient information on the disease process is known, so hazard and quantitative risk assessment can proceed using information on upstream biological perturbations. Upstream data will support improved approaches for considering developmental stage, background exposures, disease status, and other factors important to assessing hazard and risk for the whole population.
- Published
- 2008
- Full Text
- View/download PDF
231. Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells.
- Author
-
Gauger KJ, Giera S, Sharlin DS, Bansal R, Iannacone E, and Zoeller RT
- Subjects
- Animals, Cell Line, Cytochrome P-450 CYP1A1 genetics, Enzyme Induction, Female, Malate Dehydrogenase genetics, Malate Dehydrogenase metabolism, Pituitary Gland cytology, Pituitary Gland metabolism, Polychlorinated Biphenyls chemistry, Pregnancy, Rats, Rats, Sprague-Dawley, Structure-Activity Relationship, Thyroxine blood, Thyroxine metabolism, Triiodothyronine blood, Triiodothyronine metabolism, Cytochrome P-450 CYP1A1 biosynthesis, Polychlorinated Biphenyls metabolism, Receptors, Thyroid Hormone agonists
- Abstract
Background: Polychlorinated biphenyls (PCBs) may interfere with thyroid hormone (TH) signaling by reducing TH levels in blood, by exerting direct effects on TH receptors (TRs), or both., Objective: Our objective was to identify individual PCBs that directly affect TH signaling by acting on the TR., Methods: We administered a mixture of six PCB congeners based on their ortho substitution pattern, including PCBs 77 and 126 (non-ortho), PCBs 105 and 118 (mono-ortho), and PCBs 138 and 153 (di-ortho), to pregnant Sprague-Dawley rats from gestational days (G) 6 to 16. This mixture, or various combinations of the components, was also evaluated in a transient transfection system using GH3 cells., Results: The mixture reduced serum TH levels in pregnant rats on G16 but simultaneously up-regulated the expression of malic enzyme in liver. It also functioned as a TR agonist in vitro; however, none of the individual PCB congeners comprising this mixture were active in this system. Using the aryl hydrocarbon receptor (AhR) antagonist alpha-naphthoflavone, and the cytochrome P450 (CYP)1A1 antagonist ellipticine, we show that the effect of the mixture on the thyroid hormone response element required AhR and CYP1A1., Conclusions: We propose that PCB 126 induces CYP1A1 through the AhR in GH3 cells, and that CYP1A1 activates PCB 105 and/or 118 to a form a compound that acts as a TR agonist. These data suggest that some tissues may be especially vulnerable to PCBs interfering directly with TH signaling due to their capacity to express CYP1A1 in response to coplanar PCBs (or other dioxin-like molecules) if sufficient mono-ortho PCBs are present.
- Published
- 2007
- Full Text
- View/download PDF
232. Thyroid health and the environment.
- Author
-
Brent GA, Braverman LE, and Zoeller RT
- Subjects
- Humans, Potassium Iodide therapeutic use, Thyroid Diseases etiology, Thyroid Gland radiation effects, Environmental Exposure, Thyroid Gland physiology
- Published
- 2007
- Full Text
- View/download PDF
233. Developmental delays and locomotor activity in the C57BL6/J mouse following neonatal exposure to the fully-brominated PBDE, decabromodiphenyl ether.
- Author
-
Rice DC, Reeve EA, Herlihy A, Zoeller RT, Thompson WD, and Markowski VP
- Subjects
- Administration, Oral, Age Factors, Analysis of Variance, Animals, Animals, Newborn, Dose-Response Relationship, Drug, Female, Halogenated Diphenyl Ethers, Male, Mice, Mice, Inbred C57BL, Pregnancy, Sex Factors, Thyroxine blood, Behavior, Animal drug effects, Motor Activity drug effects, Phenyl Ethers administration & dosage, Polybrominated Biphenyls administration & dosage, Psychomotor Disorders chemically induced
- Abstract
After several decades of commercial use, the flame retardant chemicals polybrominated diphenyl ethers (PBDEs) and their metabolites have become pervasive environmental contaminants with a global distribution. PBDEs have entered the food chain and increasing levels can be detected in the human body. Decabrominated diphenyl ether (decaBDE) is currently the most widely used of the PBDEs in the United States. Despite its widespread use, little is known about the health effects of decaBDE. The current study examined the effects of neonatal exposure to decaBDE in the inbred C57BL6/J mouse. Neonatal male and female mice were exposed to a daily oral dose of 0, 6, or 20 mg/kg decaBDE from postnatal day 2 to 15. Three groups of endpoints were examined: the ontogeny of sensorimotor responses and serum thyroxine levels in immature animals, and locomotor activity in adult animals. In immature animals, 20 mg/kg/day produced developmental delays in the acquisition of the palpebral reflex. At this age, exposed males also showed a dose-related reduction of serum thyroxine levels. As adults, decaBDE exposure altered the normal sex- and age-specific characteristics of spontaneous locomotor activity. The most striking effect was an increase of activity during the first 1.5 h of the 2 h assessment in males exposed to 20 mg/kg/day decaBDE. These effects suggest that decaBDE is a developmental neurotoxicant that can produce long-term behavioral changes following a discrete period of neonatal exposure.
- Published
- 2007
- Full Text
- View/download PDF
234. Collision of basic and applied approaches to risk assessment of thyroid toxicants.
- Author
-
Zoeller RT
- Subjects
- Adult, Animals, Humans, Infant, Receptors, Thyroid Hormone metabolism, Risk Assessment, Thyroid Hormones metabolism, Thyroid Gland drug effects
- Abstract
Thyroid hormone (TH) is essential for normal brain development; therefore, any environmental chemical that interferes sufficiently with thyroid function, TH metabolism, or TH action may exert adverse effects on brain development. Important known differences in aspects of thyroid endocrinology between the fetus, infant, and adult allow us to identify age-dependent vulnerabilities to thyroid toxicants with some confidence. These differences include the size of the hormone pool stored in the thyroid gland at different ages as well as the age-dependent sensitivity to mild TH insufficiency. Several recent studies that describe risk assessments of the environmental contaminant, ammonium perchlorate, provide good examples of conclusions based on the selective consideration of these known aspects of the thyroid system. Specifically, authors who consider age-dependent differences in thyroid endocrinology suggest that safe levels of perchlorate should be set at relatively low levels (low parts per billion). In contrast, authors who do not consider these known age-dependent differences in thyroid endocrinology recommend safe levels of perchlorate at high (hundreds) parts per billion to parts per million. Emerging evidence indicates that a variety of high production volume chemicals can directly interact with the TH receptor. As testing paradigms are designed by regulatory agencies, these age-dependent differences in thyroid endocrinology must be considered.
- Published
- 2006
- Full Text
- View/download PDF
235. Thyroid hormone exerts site-specific effects on SRC-1 and NCoR expression selectively in the neonatal rat brain.
- Author
-
Iannacone EA, Yan AW, Gauger KJ, Dowling AL, and Zoeller RT
- Subjects
- Animals, Animals, Newborn, Binding Sites, Brain growth & development, Brain metabolism, Calmodulin-Binding Proteins analysis, Calmodulin-Binding Proteins metabolism, Female, Fetus drug effects, Gene Expression Regulation drug effects, Histone Acetyltransferases, Nerve Tissue Proteins analysis, Nerve Tissue Proteins metabolism, Neurogranin, Nuclear Proteins analysis, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Coactivator 1, Pregnancy, RNA, Messenger analysis, Rats, Rats, Sprague-Dawley, Repressor Proteins analysis, Signal Transduction, Thyroid Hormones blood, Transcription Factors analysis, Brain drug effects, Nuclear Proteins metabolism, Receptors, Steroid metabolism, Repressor Proteins metabolism, Thyroid Hormones pharmacology, Transcription Factors metabolism
- Abstract
Thyroid hormone receptors (TRs) are ligand-gated transcription factors. Recently, many coregulator proteins have been identified that interact with steroid/TRs and are required for the activation or repression of hormone sensitive genes. We tested whether steroid receptor coactivator-1 (SRC-1) and nuclear corepressor (N-CoR) expression is altered by hypothyroidism in rat brains on gestational day 16 and postnatal day 15. We found that both SRC-1 and N-CoR mRNA levels were decreased in the cortex and dentate gyrus of 6-n-propyl-2 thiouracil treated rats only on P15, while mRNA levels for both genes were increased in the same CA3 region of the brains. These findings do not support the idea that cofactors are involved in the compensatory mechanisms for conserving TH action, but they do suggest that hypothyroidism affects the responsiveness of tissues to steroid hormones by altering the expression of necessary cofactors.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.